Friday 6-6-2014 Arrowhead Research Corp (ARWR) $AR
Post# of 78
Posted On: 06/08/2014 9:44:17 PM
Friday 6-6-2014 Arrowhead Research Corp (ARWR) $ARWR opened at 14.45 hitting the high price of 14.78 and a day low of 13.77 with a total volume of 1,855,700. ARWR had a previous close of 14.06 and has been seeing an average volume of 1,524,240.
Overall Average: 32% Buy
Recent stock forum discussions about ARWR http://investorshangout.com/search?q=ARWR&...mp;yt0=Go!
Strategic Acquisitions, Clinical Data Presentations, Research Grants, and Technical Updates - Analyst Notes on Acadia, Opko Health, Arrowhead Research, Agios Pharmaceuticals and Sangamo Biosciences
PR Newswire - Fri Jun 06, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Acadia Healthcare Company, Inc. (NASDAQ: ACHC), Opko Health, Inc. (NYSE: OPK), Arrowhead Research Corp. (NASDAQ: ARWR), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Sangamo Biosciences Inc. (NASDAQ: SGMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3420-100free. (full story)
Arrowhead to Present at the Jefferies 2014 Global Healthcare Conference
Business Wire - Thu May 29, 6:30AM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Christopher Anzalone, Ph.D., President and Chief Executive Officer, will present at the Jefferies 2014 Global Healthcare Conference on Thursday, June 5, 2014 at 9:30 a.m. EDT in New York City. A live webcast of the presentation can be accessed by visiting the investors tab of the company's website at www.arrowheadresearch.com. A replay will also be archived on the website. (full story)
Nasdaq stocks posting largest percentage increases
AP - Wed May 28, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading: (full story)
Biotech 101: RNA Drugs
Brian Orelli, The Motley Fool - Motley Fool - Tue May 27, 5:00PM CDT
Disease-causing proteins can be inhibited by small-molecule drugs or by antibody drugs that bind to the protein, but there's a third class of drugs being developed that prevents the protein from being produced in the first place. They target mRNAs,... (full story)
40.0% Return Seen to Date on SmarTrend Arrowhead Research Call (ARWR)
Comtex SmarTrend(R) - Thu May 22, 10:57AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 2 months, Arrowhead Research has returned 40.01% as of today's recent price of $11.12. (full story)
Top Gainers Pre-Market Notes -- Research on Millennial Media, Demandware, Arrowhead Research, and KEYW Holding
PR Newswire - Tue May 20, 8:12AM CDT
The US markets saw a positive sentiment on Monday, May 19, 2014, with the NASDAQ Composite closing at 4,125.82, up 0.86%, the Dow Jones Industrial Average ending the session at 16,511.86, up 0.12% and the S&P 500 edging 0.38% higher to finish the trading session at 1,885.08. The session saw a positive impact from Financials, Information Technology and Health Care sectors along with a drag from Consumer Staples, Utilities and Telecommunication Services sectors. A number of stocks saw large movements, including Millennial Media Inc. (NYSE: MM), Demandware Inc. (NASDAQ: DWRE), Arrowhead Research Corporation (NASDAQ: ARWR) and The KEYW Holding Corporation (NASDAQ: KEYW). Free technical research on MM, DWRE, ARWR and KEYW can be downloaded upon signing up at: (full story)
Earnings Release Results, and Leadership Appointments - Analyst Notes on Halozyme, MannKind, Arrowhead, Idera and BioCryst
PR Newswire - Fri May 16, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Halozyme Therapeutics, Inc. (NASDAQ: HALO), MannKind Corp. (NASDAQ: MNKD), Arrowhead Research Corp. (NASDAQ: ARWR), Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) and BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2534-100free. (full story)
Downtrend Call Working As Arrowhead Research Stock Falls 40.5% (ARWR)
Comtex SmarTrend(R) - Thu May 15, 9:35AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 2 months, Arrowhead Research has returned 40.54% as of today's recent price of $11.02. (full story)
Shares of ARWR Down 45.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu May 08, 9:08AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 2 month, Arrowhead Research has returned 45.94% as of today's recent price of $10.02. (full story)
Metastatic Liver Cancer - Pipeline Review, H1 2014: 8 Companies and 8 Drugs Profiled
M2 - Thu May 08, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b7pjhn/metastatic_liver) has announced the addition of the "Metastatic Liver Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Liver Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Liver Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Liver Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Liver Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Liver Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved: - Arrowhead Research Corporation - Celsion Corporation - F. Hoffmann-La Roche Ltd. - Mirna Therapeutics, Inc. - PreScience Labs, LLC - Provectus Biopharmaceuticals, Inc. - Tekmira Pharmaceuticals Corp. - Transgene Biotek Limited Drug Profiles: - RG-7686 - rose bengal sodium - MRX-34 - TKM-PLK1 - PSL-001 - doxorubicin liposomal - TBL-0404 - Peptide Drug Conjugate For Metastatic Liver Cancer For more information visit http://www.researchandmarkets.com/research/b7...atic_liver (full story)
Arrowhead to Present at Upcoming Scientific Conferences
Business Wire - Tue May 06, 3:02PM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will present at multiple scientific conferences in May. (full story)
Arrowhead Reports Fiscal 2014 Second Quarter Financial Results
Business Wire - Tue May 06, 3:01PM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2014 second quarter ended March 31, 2014. The company is hosting a conference call at 4:30 p.m. EDT to discuss results. To participate in the conference call, please dial 855-215-6159 (toll free from the US) or 315-625-6887 (for international callers) and enter Conference ID 35127223. Investors may also access a live audio webcast of this conference call on the Company's website at http://www.arrowheadresearch.com/presentations. (full story)
Arrowhead to Present at Deutsche Bank 39th Annual Health Care Conference
Business Wire - Thu May 01, 6:31AM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Bruce Given, M.D., Chief Operating Officer, will present at the Deutsche Bank 39th Annual Health Care Conference on Thursday, May 8, 2014 at 12:50 p.m. EDT at the InterContinental hotel in Boston. (full story)
Arrowhead to Report Fiscal 2014 Second Quarter Financial Results
Business Wire - Tue Apr 29, 3:06PM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2014 second quarter ended March 31, 2014, on Tuesday, May 6, 2014, at 4:30 p.m. EDT. To participate in the conference call, please dial 855-215-6159 (toll free from the US) or 315-625-6887 (for international callers) and enter Conference ID 35127223. Investors may also access a live audio webcast of this conference call on the Company's website at http://www.arrowheadresearch.com/presentations. (full story)
Top Gainers on the Move -- Research on Arrowhead Research, Endocyte, Ambac Financial, and ZIOPHARM Oncology
PR Newswire - Wed Apr 23, 11:40AM CDT
The trading session on Tuesday, April 22, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,514.37, up 0.40% and the NASDAQ Composite closed at 4,161.46, up 0.97%. The S&P 500 finished the session 0.41% higher at 1,879.55. The gains were broad based as eight out of ten sectors finished on a positive note. A number of stocks saw large movements, including Arrowhead Research Corp. (NASDAQ: ARWR), Endocyte Inc. (NASDAQ: ECYT), Ambac Financial Group Inc. (NASDAQ: AMBC) and ZIOPHARM Oncology Inc. (NASDAQ: ZIOP). Free technical research on ARWR, ECYT, AMBC and ZIOP can be downloaded upon signing up at: (full story)
Arrowhead Research Shares Down 29.9% Since SmarTrend's Sell Call (ARWR)
Comtex SmarTrend(R) - Wed Apr 23, 10:57AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 1 month, Arrowhead Research has returned 29.86% as of today's recent price of $13.00. (full story)
Overall Average: 32% Buy
Recent stock forum discussions about ARWR http://investorshangout.com/search?q=ARWR&...mp;yt0=Go!
Strategic Acquisitions, Clinical Data Presentations, Research Grants, and Technical Updates - Analyst Notes on Acadia, Opko Health, Arrowhead Research, Agios Pharmaceuticals and Sangamo Biosciences
PR Newswire - Fri Jun 06, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Acadia Healthcare Company, Inc. (NASDAQ: ACHC), Opko Health, Inc. (NYSE: OPK), Arrowhead Research Corp. (NASDAQ: ARWR), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Sangamo Biosciences Inc. (NASDAQ: SGMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3420-100free. (full story)
Arrowhead to Present at the Jefferies 2014 Global Healthcare Conference
Business Wire - Thu May 29, 6:30AM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Christopher Anzalone, Ph.D., President and Chief Executive Officer, will present at the Jefferies 2014 Global Healthcare Conference on Thursday, June 5, 2014 at 9:30 a.m. EDT in New York City. A live webcast of the presentation can be accessed by visiting the investors tab of the company's website at www.arrowheadresearch.com. A replay will also be archived on the website. (full story)
Nasdaq stocks posting largest percentage increases
AP - Wed May 28, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading: (full story)
Biotech 101: RNA Drugs
Brian Orelli, The Motley Fool - Motley Fool - Tue May 27, 5:00PM CDT
Disease-causing proteins can be inhibited by small-molecule drugs or by antibody drugs that bind to the protein, but there's a third class of drugs being developed that prevents the protein from being produced in the first place. They target mRNAs,... (full story)
40.0% Return Seen to Date on SmarTrend Arrowhead Research Call (ARWR)
Comtex SmarTrend(R) - Thu May 22, 10:57AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 2 months, Arrowhead Research has returned 40.01% as of today's recent price of $11.12. (full story)
Top Gainers Pre-Market Notes -- Research on Millennial Media, Demandware, Arrowhead Research, and KEYW Holding
PR Newswire - Tue May 20, 8:12AM CDT
The US markets saw a positive sentiment on Monday, May 19, 2014, with the NASDAQ Composite closing at 4,125.82, up 0.86%, the Dow Jones Industrial Average ending the session at 16,511.86, up 0.12% and the S&P 500 edging 0.38% higher to finish the trading session at 1,885.08. The session saw a positive impact from Financials, Information Technology and Health Care sectors along with a drag from Consumer Staples, Utilities and Telecommunication Services sectors. A number of stocks saw large movements, including Millennial Media Inc. (NYSE: MM), Demandware Inc. (NASDAQ: DWRE), Arrowhead Research Corporation (NASDAQ: ARWR) and The KEYW Holding Corporation (NASDAQ: KEYW). Free technical research on MM, DWRE, ARWR and KEYW can be downloaded upon signing up at: (full story)
Earnings Release Results, and Leadership Appointments - Analyst Notes on Halozyme, MannKind, Arrowhead, Idera and BioCryst
PR Newswire - Fri May 16, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Halozyme Therapeutics, Inc. (NASDAQ: HALO), MannKind Corp. (NASDAQ: MNKD), Arrowhead Research Corp. (NASDAQ: ARWR), Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) and BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2534-100free. (full story)
Downtrend Call Working As Arrowhead Research Stock Falls 40.5% (ARWR)
Comtex SmarTrend(R) - Thu May 15, 9:35AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 2 months, Arrowhead Research has returned 40.54% as of today's recent price of $11.02. (full story)
Shares of ARWR Down 45.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu May 08, 9:08AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 2 month, Arrowhead Research has returned 45.94% as of today's recent price of $10.02. (full story)
Metastatic Liver Cancer - Pipeline Review, H1 2014: 8 Companies and 8 Drugs Profiled
M2 - Thu May 08, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b7pjhn/metastatic_liver) has announced the addition of the "Metastatic Liver Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Liver Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Liver Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Liver Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Liver Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Liver Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved: - Arrowhead Research Corporation - Celsion Corporation - F. Hoffmann-La Roche Ltd. - Mirna Therapeutics, Inc. - PreScience Labs, LLC - Provectus Biopharmaceuticals, Inc. - Tekmira Pharmaceuticals Corp. - Transgene Biotek Limited Drug Profiles: - RG-7686 - rose bengal sodium - MRX-34 - TKM-PLK1 - PSL-001 - doxorubicin liposomal - TBL-0404 - Peptide Drug Conjugate For Metastatic Liver Cancer For more information visit http://www.researchandmarkets.com/research/b7...atic_liver (full story)
Arrowhead to Present at Upcoming Scientific Conferences
Business Wire - Tue May 06, 3:02PM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will present at multiple scientific conferences in May. (full story)
Arrowhead Reports Fiscal 2014 Second Quarter Financial Results
Business Wire - Tue May 06, 3:01PM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2014 second quarter ended March 31, 2014. The company is hosting a conference call at 4:30 p.m. EDT to discuss results. To participate in the conference call, please dial 855-215-6159 (toll free from the US) or 315-625-6887 (for international callers) and enter Conference ID 35127223. Investors may also access a live audio webcast of this conference call on the Company's website at http://www.arrowheadresearch.com/presentations. (full story)
Arrowhead to Present at Deutsche Bank 39th Annual Health Care Conference
Business Wire - Thu May 01, 6:31AM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Bruce Given, M.D., Chief Operating Officer, will present at the Deutsche Bank 39th Annual Health Care Conference on Thursday, May 8, 2014 at 12:50 p.m. EDT at the InterContinental hotel in Boston. (full story)
Arrowhead to Report Fiscal 2014 Second Quarter Financial Results
Business Wire - Tue Apr 29, 3:06PM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2014 second quarter ended March 31, 2014, on Tuesday, May 6, 2014, at 4:30 p.m. EDT. To participate in the conference call, please dial 855-215-6159 (toll free from the US) or 315-625-6887 (for international callers) and enter Conference ID 35127223. Investors may also access a live audio webcast of this conference call on the Company's website at http://www.arrowheadresearch.com/presentations. (full story)
Top Gainers on the Move -- Research on Arrowhead Research, Endocyte, Ambac Financial, and ZIOPHARM Oncology
PR Newswire - Wed Apr 23, 11:40AM CDT
The trading session on Tuesday, April 22, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,514.37, up 0.40% and the NASDAQ Composite closed at 4,161.46, up 0.97%. The S&P 500 finished the session 0.41% higher at 1,879.55. The gains were broad based as eight out of ten sectors finished on a positive note. A number of stocks saw large movements, including Arrowhead Research Corp. (NASDAQ: ARWR), Endocyte Inc. (NASDAQ: ECYT), Ambac Financial Group Inc. (NASDAQ: AMBC) and ZIOPHARM Oncology Inc. (NASDAQ: ZIOP). Free technical research on ARWR, ECYT, AMBC and ZIOP can be downloaded upon signing up at: (full story)
Arrowhead Research Shares Down 29.9% Since SmarTrend's Sell Call (ARWR)
Comtex SmarTrend(R) - Wed Apr 23, 10:57AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 1 month, Arrowhead Research has returned 29.86% as of today's recent price of $13.00. (full story)
(0)
(0)